Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of bortezomib + dexamethasone + decitabine in relapsed/refractory multiple myeloma
ChiCTR-OPC-17013860Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bortezomib, dexamethasone and decitabine in multiple myeloma (MM), sponsored by Henan Cancer Hospital. Primary endpoint: Immunofixation electrophoresis. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
bortezomibdexamethasonedecitabine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR-OPC-17013860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013860.